Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

NCT03452501 · clinicaltrials.gov ↗

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammatory Bowel Diseases
Crohn Disease
Fistulizing Crohn's Disease
Ulcerative Colitis

Interventions

DRUG: Infliximab

Sponsor

Hikma Pharmaceuticals LLC